![Connie Matsui](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Connie Matsui
Presidente presso
ARTELO BIOSCIENCES, INC.
Patrimonio netto: 146 444 $ in data 31/05/2026
Profilo
Connie L. Matsui è presidente di Sutro Biopharma, Inc., presidente di Artelo Biosciences, Inc., presidente di Halozyme Therapeutics, Inc. e presidente di Balboa Park Conservancy. Matsui è stata precedentemente impiegata come presidente nazionale presso Girl Scouts of the USA, vicepresidente esecutivo presso Biogen Idec New Ventures, Inc., vicepresidente senior presso IDEC Pharmaceuticals Corp., vicepresidente esecutivo-Knowledge & Innovation Networks presso Biogen Idec, Inc. e presidente e amministratore delegato presso The San Diego Foundation. Si è laureata alla Stanford University e ha conseguito un MBA alla Stanford University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 05/06/2026 | 5.000 ( 0,03% ) | 146 150 $ | 31/05/2026 | |
| 20/02/2026 | 210 ( 0,01% ) | 294 $ | 31/05/2026 |
Posizioni attive di Connie Matsui
| Società | Posizione | Inizio |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Presidente | 02/05/2017 |
| SUTRO BIOPHARMA, INC. | Presidente | 24/06/2019 |
Precedenti posizioni note di Connie Matsui
| Società | Posizione | Fine |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Presidente | - |
The San Diego Foundation
 The San Diego Foundation Miscellaneous Commercial ServicesCommercial Services Provides information about charitable giving and community needs | Amministratore Delegato | 01/05/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2009 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01/01/2009 |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Corporate Officer/Principal | 31/03/2008 |
Formazione di Connie Matsui
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
73
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
The San Diego Foundation
The San Diego Foundation Miscellaneous Commercial ServicesCommercial Services Provides information about charitable giving and community needs | Commercial Services |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Sutro Biopharma, Inc.
 Sutro Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops new products in protein vaccines and therapeutics | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes targeted immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Girl Scouts of the USA
 Girl Scouts of the USA Miscellaneous Commercial ServicesCommercial Services Helps to build character and skills for girls | Commercial Services |
Balboa Park Conservancy
 Balboa Park Conservancy Miscellaneous Commercial ServicesCommercial Services Provides advocacy services | Commercial Services |
